Vertex Pharmaceuticals Incorporated (VRTX) : Clearbridge Investments reduced its stake in Vertex Pharmaceuticals Incorporated by 3.64% during the most recent quarter end. The investment management company now holds a total of 7,299,009 shares of Vertex Pharmaceuticals Incorporated which is valued at $689,172,430 after selling 275,774 shares in Vertex Pharmaceuticals Incorporated , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Vertex Pharmaceuticals Incorporated makes up approximately 0.78% of Clearbridge Investments’s portfolio.
Other Hedge Funds, Including , Canada Pension Plan Investment Board reduced its stake in VRTX by selling 69,149 shares or 52.89% in the most recent quarter. The Hedge Fund company now holds 61,584 shares of VRTX which is valued at $5,125,020. Vertex Pharmaceuticals Incorporated makes up approx 0.02% of Canada Pension Plan Investment Board’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in VRTX in the latest quarter, The investment management firm added 144,397 additional shares and now holds a total of 6,492,221 shares of Vertex Pharmaceuticals Incorporated which is valued at $540,282,632. Vertex Pharmaceuticals Incorporated makes up approx 0.09% of Blackrock Institutional Trust Company N.a.’s portfolio.Homrich Berg reduced its stake in VRTX by selling 79 shares or 3.04% in the most recent quarter. The Hedge Fund company now holds 2,521 shares of VRTX which is valued at $199,058. Vertex Pharmaceuticals Incorporated makes up approx 0.02% of Homrich Berg’s portfolio.Nippon Life Insurance Co reduced its stake in VRTX by selling 106 shares or 0.95% in the most recent quarter. The Hedge Fund company now holds 11,096 shares of VRTX which is valued at $864,156. Vertex Pharmaceuticals Incorporated makes up approx 0.02% of Nippon Life Insurance Co’s portfolio.
Vertex Pharmaceuticals Incorporated closed down -1.76 points or -1.93% at $89.44 with 12,65,388 shares getting traded on Monday. Post opening the session at $90.94, the shares hit an intraday low of $89 and an intraday high of $91.48 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.16 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Oct 25, 2016. Analyst had a consensus of $0.19. The company had revenue of $413.78 million for the quarter, compared to analysts expectations of $417.80 million. The company’s revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.13 EPS.
Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. H.C. Wainwright Downgraded Vertex Pharmaceuticals Incorporated on Oct 24, 2016 to ” Neutral”, Price Target of the shares are set at $85.Company shares were Reiterated by Stifel on Sep 15, 2016 to “Buy”, Firm has raised the Price Target to $ 109 from a previous price target of $105 .Vertex Pharmaceuticals Incorporated was Initiated by Raymond James to “Mkt Perform” on Sep 13, 2016.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Companys product KALYDECO is available in the market.